Miastenia grave autoimune

aspectos clínicos e experimentais

Autores

  • Andrezza Sossai Rodrigues de Carvalho
  • Alexandre Valotta da Silva
  • Francis Meire Fáveroi Ortensi
  • Sissy Veloso Fontes
  • Acary Souza Bulle Oliveira

DOI:

https://doi.org/10.34024/rnc.2005.v13.10352

Palavras-chave:

Miastenia Gravis, Fisioterapia, Atividade Motora

Resumo

A Miastenia Grave (MG) é caracterizada por uma alteração na transmissão nervo músculo, decorrente da deficiência, bloqueio e destruição de receptores de acetilcolina na junção neuromuscular. A presente revisão tem o objetivo de trazer informações atuais sobre a MG, abrangendo os seguintes aspectos: histórico; fisiopatologia; procedimentos diagnósticos; classificação e tratamento da doença. Além disso, revisamos os principais modelos experimentais que mimetizam as manifestações clínicas observadas na MG humana.

Métricas

Carregando Métricas ...

Downloads

Não há dados estatísticos.

Referências

1. Adams RD et al. Miastenia grave e distúrbios correlatos da transmissão neuromuscular. In: Adams RD, Victor M. Neurologia. Traduzido por: Amaury J Cruz Junior et al. 6º ed. Rio de Janeiro: Mac Graw Hill; 1998, p 957-968.
2. Engel AG. Acquired autoimmune myasthenia gravis. In: Engel AG, Franzini-Armstrong. Myologi. 2ºed. [S.L]: Mc Graw Hill; 1994, p 1769-1797.
3. Gomes MM. Doenças. In: Gomes MM. Marcos históricos da neurologia. Rio de Janeiro: Científica Nacional; 1997, p 79-114.
4. Rowland LP. Doença da transmissão química na sinapse neuromuscular: Miastenia grave. In: Kandel ER, Schwartz JH, Jessel TM. Princípios da neurociência. Traduzido por: Andréa da Silva Torrão. 4a ed. São Paulo: Manole; 2003, p 298-308.
5. Simpson JA. Myasthenia gravis: A new hypothesis. Scot Med J 1960; 5:419-422.
6. Blalock, A, Masson, MF, Morgan, Hj, Riven, SS. Myasthenia gravis and tumors of the thymic region: Report of case in which the tumor was removed. Ann. Surg 1939; 110:544-561.
7. Harvey AM, Lilienthal JL Jr., Talbot SA. Observation on the nature of myasthenia gravis the phenomena of facilitation and depression of neuromuscular transmission. Bull Jhons Hopkins Hosp. 1941; 69:547-565
8. Chang CC, Lee CY. Electrophysiological study of neuromuscular blocking action of cobra neurotoxin. Br J Pharm Chemother 1966; 28:172-181.
9. Frambrough DM, Drachamn DB. Neuromuscular junction in myasthenia gravis: Decreased acetylholine receptors. Sciene 1973; 182:293-295.
10. Phillips II LH. The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003; 998:407-412.
11. Penn AS, ROWLAND LP. Myasthenia gravis. In: ROWLAND LP. Merritt’s neurology. 10ºed Philadelphia: Lippincott Willians e Wilkinkns; 2000. p.721-726
12. Drachman DB. Myasthenia gravis and other diseases of the neuromuscular junction. In: Fauci AS et al. Harrison’s principles of internal medicine. 15ºed. [S.L]: Mc Graw Hill; 2001. p.2515-2520.
13. Mora A, Cortès C, Mateo EM, Pla M, Cabarrocas E. Miastenia grave. Rev Esp Anestesiol. Reanim 1990; 37:284-290.
14. Zuleta JJ, Fanbug BL. Respiratory dysfunction in myasthenia gravis. Clinics in Chest Medicine 1994; 15:683-671.
15. Cambier J, Masson M, Dehen H. Patologia muscular. In: Cambier J, Masson M, Dehen H. Manual de neurologia. Traduzido por: Sergio Augusto Pereira Noris. Rio de Janeiro: Masson do Brasil; 1980. p.518-536.
16. Jacobs-Burleigh A. Synapse e transmissão sináptica. In: Ekman-Lundy L. Neurociência: Fundamentos para a reabilitação. Traduzido por: Charles A Esbérard. Rio de Janeiro: Granabara Koogan; 2000. p. 33-42.
17. Chaudhuri A, Obehan P. Fatigue in neurological disorders. The Lancet 2004; 363:978-987. 2004.
18. Osserman KE, Genkis G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. MT Sinai J Med 1971; 38:497-537.
19. Arora NS, Gal TJ. Cough dynamics during progressive expiratory muscle weakness in healthy curarized subjects. J Appl Physiol 1981; 51:494.
20. Bennett JC, Plum F. Neurologia. In: Bennett JC, Plum F. Neurologia. Cecil tratado de medicina interna. Traduzido por: Maria F Azevedo. 20ºed. Rio de Janeiro: Guanabara Koogan; 1997. p.2394-2397.
21. Compston DA, Vicent A, Newsom-Davis J et al. Clinical, pathological, HLA antigen and immunological evidence for heterogeneity in myasthenia gravis. Brain 1980; 103:579.
22. Limburg PC, Hummel-Tapel E et al. Antiacetylcholine receptor antibodien in myasthenia gravis. Part I. Relation to clinical parameters in 250 patients. J Neurol Sci 1983; 58:357-362.
23. Calcaterra TC, Steern F. The otolatingologist’s role in myasthenia gravis. Am Acad Ophthalmol Otolaryngol 1972; 76:308.
24. Oliveira ABS, Gabbai AA. Doenças neuromusculares. In: Prado FC, Ramos JA, Valle JR. Atualização terapêutica: Manual prático de diagnóstico e tratamento. 20ºed. São Paulo: Artes Médicas; 2001. p.815-826.
25. Lindstrom J. Experimental autoimmune myasthenia gravis. J Nerol Neuros Psych 1980; 43:568-576.
26. Gronseth GS, Barohn RJ. Pratice parameter: Tymectomy of autoimmune myasthenia gravis (an evidence-based review). Neurology 2000;55:7-15.
27. Werneck LC, Cunha FMB, Scola RL. Myasthenia gravis: a retrospective study comparing tymectomy to conservative treatment. Acta Neurol Scand 2000; 101:41-46.
28. Kennan SP et al. Ventilatory muscle strength and endurance in myasthenia gravis. Eur Respir J 1995; 8:1130-1135.
29. Weiner P et al. Respiratory muscle training in patients with moderate to severe myasthenia gravis. Can J Neurol Sci 1998; 25:236-241.
30. Lena-Eva L, Lindberg C, Andersen O. Physical training effects in myasthenia gravis. Arch Phys Med Rehabil 1993; 74:1178-1180.
31. Nachmanson, D. Chemical and molecular basis of nerve activity. New York: Academic Press, 1959
32. Kiefer H, Lindstrom J, Lennox ES, Singer SJ. Photo-affinity labeling of specific acetylcoline binding sites on membranes. Proc Natl Acad Sci 1970; 67:1688-1694.
33. Lindstrom JM. Nicotinic acetylcholine receptors of muscle and nerves: Comparison of their structures, functional roles and vulnerability to pathology. Ann NY Acad Sci 2003; 998:41-52.
34. Karlin A, Akabas MH. Toward a structural basis for the function of nicotinic acetylcholine receptors and the cousis. Neuron 1995; 15:1231-1244.
35. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science 1973; 180:871-873.
36. Lennon VA, Lindstrom J, Seybold ME. Experimental autoimune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975; 141:365-1375.
37. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. J Clin Immunol Immunopath 1977; 7:36-43.
38. Baggi F et al. Immunization with rat, but not Torpedo-derived 97-116 peptide of the Ach alfa-subunit induces experi
mental myasthenia gravis in Lewis rat. Ann NY Acad Sci 2003; 998:391-394.
39. Baggi F et al. Breakdown of tolerance to a self-peptide of acetylcholine receptor alfa-subunit induces experimental myasthenia gravis in rats. J Immunol 2004; 172:2697-2703.
40. Guo-Bao X, Hans L. Rat model as tool to develop new immunotherapies. Immunol Rev 2001; 184:117-128.
41. Lindstrom JM, Einarson B, Lennon VA, Seybold ME. Pathological mechanisms in EAMG I: Imunogenicity of syngenic muscle acetylcholine receptor and quantitative extraction of receptor and anti-body receptor complexes for muscles of rats with experimental autoimmune myasthenia gravis. J Exp Med 1976; 144:726-738.
42. Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH. Pathological mechanisms in EAMG II: Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976; 144:739-753.
43. Kandel ER, Siegelbaum AS. Sinalização na sinapse neuromuscular: transmissão por ativação direta. In: kandel ER et al. Princípios da neurociência. 4ºed. Traduzido por: Andréa S Torrão. São Paulo: Manole; 2003. p.187-205.
44. Engel AG, Lindstrom JM, Lambert EH, Lennon VA. Ultra structural localization of the acetylcholine receptor in myasthenia gravis and its experimental autoimmune model. Neurology 1977; 27:307-315.
45. Maiti PK, Feferman T, Im SH, Soroujon MC, Fuchs S. Immunosupression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 2004; 152: 112-120.
46. Im SH, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol 2000; 116:161-168.
47. Vang ZY, Quião J, Hans L. Supression fo experimental autoimmune myasthenia gravis by oral administração of acetylcholine receptor. J Neuroimmunol 1993; 44:209-214.
48. Silva S, Mclutosh K, Blum JE, Order S, Mellits D, Drachamn DB. Total lymphoid irradiation and antigen-specific tolerance: future therapy for experimental autoimmune myasthenia gravis. J Neuroimmunol 1990; 29:93-103.
49. Takamori M, Mori M, Kassai M. Experimental autoimmune myasthenia gravis and cholinergic ionnphore: An eletrophisiologic stud. Neurology 1979; 29-945-950.

Downloads

Publicado

2005-09-30

Como Citar

Carvalho, A. S. R. de, Silva, A. V. da, Ortensi, . F. M. F., Fontes, S. V., & Oliveira, A. S. B. (2005). Miastenia grave autoimune: aspectos clínicos e experimentais. Revista Neurociências, 13(3), 138–144. https://doi.org/10.34024/rnc.2005.v13.10352

Edição

Seção

Artigos de Revisão

Artigos Semelhantes

<< < 6 7 8 9 10 11 12 13 14 15 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.

Artigos mais lidos pelo mesmo(s) autor(es)

1 2 3 4 5 6 7 > >>